3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 4
1
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
28
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neoplasms
3
Neoplasm Metastasis
3
Prostatic Neoplasms, Castration-Resistant
2
Prostate Cancer Metastatic
2
Metastatic Hormone Sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
mCRPC
1
Recurrence
1
Prostatic Diseases
1
Patient Preference
1
Metastatic Castration-resistent Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer
1
MCRPC
1
Genital Diseases, Male
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Abiraterone Acetate
2
rucaparib
1
enzalutamide
1
Prednisone
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Metastatic Castration Resistant Prostate Cancer
×
enzalutamide
×
Clear all
NCT02975934
2025-07-25
TRITON3
pharmaand GmbH
Phase 3
Completed
405 enrolled
34 charts
1 FDA